Goldman Sachs’s Cidara Therapeutics CDTX Stock Holding History

Goldman Sachs’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,100	Closed	-$1.64M	–	6483
2025 Q3	$1.64M	Buy	+17,100	New	+$1.09M	﹤0.01%	4649

Goldman Sachs's CDTX Position: Q1 2026 in Review

Goldman Sachs sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 377,718 shares — an estimated $83.4M sold.

Goldman Sachs first reported a position in CDTX in Q2 2015 and held it in 31 quarters. The position peaked at $83.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Goldman Sachs reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Goldman Sachs sold 377,718 Cidara Therapeutics shares in Q1 2026, an estimated $83.4M.
Goldman Sachs first reported a position in Cidara Therapeutics in Q2 2015 and held it in 31 quarters.
Goldman Sachs's Cidara Therapeutics position peaked at $83.4M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.